Inhibition of neuroblastoma tumor growth by ketogenic diet and/or calorie restriction in a CD1-nu mouse model

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Morscher, Raphael Johannes ^a,b   Aminzadeh Gohari, Sepideh ^a   Feichtinger, RenéGunther ^a   Mayr, Johannes Adalbert ^a   Lang, Roland ^a   Neureiter, Daniel ^a   Sperl, Wolfgang ^a   Kofler, Barbara ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

3 OXOACID COENZYME A TRANSFERASE; GLUCOSE; HISTONE H3; KI 67 ANTIGEN; LONG CHAIN FATTY ACID; MITOCHONDRIAL DNA; SUCCINYL COENZYME A:3 KETOACID COENZYME A TRANSFERASE 1 PROTEIN; UNCLASSIFIED DRUG; 3-KETOACID COA-TRANSFERASE; CD1 ANTIGEN; COENZYME A TRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CALORIC RESTRICTION; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE G0 PHASE; CONTROLLED STUDY; DNA CONTENT; ENZYME ACTIVITY; G1 PHASE CELL CYCLE CHECKPOINT; GENE DOSAGE; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; KETOGENIC DIET; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; SENSITIVITY ANALYSIS; THERAPY EFFECT; TUMOR XENOGRAFT; WESTERN BLOTTING; ADAPTATION; ANIMAL; CELL PROLIFERATION; DIET THERAPY; DISEASE MODEL; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; MITOCHONDRION; MORTALITY; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

MUS; MUS MUSCULUS;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; ANTIGENS, CD1; CALORIC RESTRICTION; CELL LINE, TUMOR; CELL PROLIFERATION; COENZYME A-TRANSFERASES; DISEASE MODELS, ANIMAL; DNA, MITOCHONDRIAL; G1 PHASE CELL CYCLE CHECKPOINTS; GENE DOSAGE; HUMANS; KETOGENIC DIET; MICE; MITOCHONDRIA; NEUROBLASTOMA; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84935462806     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129802     Document Type: Article

References (88)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; 3 (3):203-16. doi: 10.1038/nrc1014 PMID: 12612655.
2. Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KM, et al. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatric blood & cancer. 2013; 60(6):985-93. doi: 10.1002/pbc.24433 PMID: 23255319.
3. Feichtinger RG, Zimmermann F, Mayr JA, Neureiter D, Hauser-Kronberger C, Schilling FH, et al. Low aerobic mitochondrial energy metabolism in poorly- or undifferentiated neuroblastoma. BMC cancer. 2010; 10:149. Epub 2010/04/20. doi: 10.1186/1471-2407-10-149 PMID: 20398431; PubMed Central PMCID: PMC2861660.
4. Schneider L, Giordano S, Zelickson BR, M SJ, G AB, Ouyang X, et al. Differentiation of SH-SY5Y cells to a neuronal phenotype changes cellular bioenergetics and the response to oxidative stress. Free radical biology & medicine. 2011; 51(11):2007-17. doi: 10.1016/j.freeradbiomed.2011.08.030 PMID: 21945098; PubMed Central PMCID: PMC3208787.
5. Chiang MC, Cheng YC, Chen HM, Liang YJ, Yen CH. Rosiglitazone promotes neurite outgrowth and mitochondrial function in N2A cells via PPARgamma pathway. Mitochondrion. 2013; 14C:7-17. doi: 10.1016/j.mito.2013.12.003 PMID: 24370585.
6. Xun Z, Lee DY, Lim J, Canaria CA, Barnebey A, Yanonne SM, et al. Retinoic acid-induced differentiation increases the rate of oxygen consumption and enhances the spare respiratory capacity of mitochondria in SH-SY5Y cells. Mechanisms of ageing and development. 2012; 133(4):176-85. doi: 10.1016/j.mad.2012.01.008 PMID: 22336883; PubMed Central PMCID: PMC3357086.
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. doi: 10.1016/j.cell.2011.02.013 PMID: 21376230.
8. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029-33. Epub 2009/05/23. doi: 324/5930/1029 [pii] doi: 10.1126/science.1160809 PMID: 19460998; PubMed Central PMCID: PMC2849637
9. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer research. 2006; 66 (18):8927-30. Epub 2006/09/20. doi: 66/18/8927 [pii] doi: 10.1158/0008-5472.CAN-06-1501 PMID: 16982728.
10. Warburg O. U¨ber den Stoffwechsel der Carcinomzelle. Die Naturwissenschaften. 1924; 50:1131-7.
11. Meierhofer D, Mayr JA, Foetschl U, Berger A, Fink K, Schmeller N, et al. Decrease of mitochondrial DNA content and energy metabolism in renal cell carcinoma. Carcinogenesis. 2004; 25(6):1005-10. PMID: 14764459.
12. Feichtinger RG, Neureiter D, Mayr JA, Zimmermann FA, Berthold F, Jones N, et al. Loss of mitochondria in ganglioneuromas. Front Biosci (Elite Ed). 2011; 3:179-86. Epub 2011/01/05. PMID: 21196296.
13. Feichtinger RG, Neureiter D, Royer-Pokora B, Mayr JA, Zimmermann FA, Jones N, et al. Heterogeneity of mitochondrial energy metabolism in classical triphasic Wilms' tumor. Front Biosci (Elite Ed). 2011; 3:187-93. Epub 2011/01/05. PMID: 21196297.
14. Feichtinger RG, Zimmermann FA, Mayr JA, Neureiter D, Ratschek M, Jones N, et al. Alterations of respiratory chain complexes in sporadic pheochromocytoma. Front Biosci (Elite Ed). 2011; 3:194-200. Epub 2011/01/05. PMID: 21196298.
15. Mayr JA, Meierhofer D, Zimmermann F, Feichtinger R, Kogler C, Ratschek M, et al. Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(8):2270-5. PMID: 18413815. doi: 10.1158/1078-0432.CCR-07-4131
16. Zimmermann FA, Mayr JA, Feichtinger R, Neureiter D, Lechner R, Koegler C, et al. Respiratory chain complex I is a mitochondrial tumor suppressor of oncocytic tumors. Front Biosci (Elite Ed). 2011; 3:315-25. Epub 2011/01/05. PMID: 21196312.
17. Zimmermann FA, Mayr JA, Neureiter D, Feichtinger R, Alinger B, Jones ND, et al. Lack of complex I is associated with oncocytic thyroid tumours. British journal of cancer. 2009; 100(9):1434-7. PMID: 19352385. doi: 10.1038/sj.bjc.6605028
18. Lopez-Rios F, Sanchez-Arago M, Garcia-Garcia E, Ortega AD, Berrendero JR, Pozo-Rodriguez F, et al. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer research. 2007; 67(19):9013-7. doi: 10.1158/0008-5472.CAN-07-1678 PMID: 17909002.
19. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002; 2(9):683-93. doi: 10.1038/nrc882 PMID: 12209157.
20. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nature reviews Drug discovery. 2011; 10(9):671-84. doi: 10.1038/nrd3504 PMID: 21878982.
21. Zhang D, Li J, Wang F, Hu J, Wang S, Sun Y. 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer letters. 2014; 355(2):176-83. doi: 10.1016/j.canlet.2014.09.003 PMID: 25218591.
22. Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, et al. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013; 71(2):523-30. Epub 2012/12/12. doi: 10.1007/s00280-012-2045-1 PMID: 23228990.
23. Jones NP, Schulze A. Targeting cancer metabolism-aiming at a tumour's sweet-spot. Drug discovery today. 2012; 17(5-6):232-41. doi: 10.1016/j.drudis.2011.12.017 PMID: 22207221.
24. Butler EB, Zhao Y, Munoz-Pinedo C, Lu J, Tan M. Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance. Cancer research. 2013; 73(9):2709-17. doi: 10.1158/0008-5472.CAN-12-3009 PMID: 23610447; PubMed Central PMCID: PMC3644012.
25. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. 2010; 10(4):267-77. Epub 2010/03/20. doi: nrc2817 [pii] doi: 10.1038/nrc2817 PMID: 20300106.
26. Lv M, Zhu X, Wang H, Wang F, Guan W. Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and meta-analysis. PloS one. 2014; 9(12):e115147. Epub 2014/12/17. doi: 10.1371/journal.pone.0115147 PMID: 25502434; PubMed Central PMCID: PMCPmc4263749.
27. Allen BG, Bhatia SK, Buatti JM, Brandt KE, Lindholm KE, Button AM, et al. Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19(14):3905-13. doi: 10.1158/1078-0432.CCR-12-0287 PMID: 23743570; PubMed Central PMCID: PMC3954599.
28. Rieger J, Bahr O, Maurer GD, Hattingen E, Franz K, Brucker D, et al. ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. International journal of oncology. 2014; 44(6):1843-52. Epub 2014/04/15. doi: 10.3892/ijo.2014.2382 PMID: 24728273.
29. Chu-Shore CJ, Thiele EA. Tumor growth in patients with tuberous sclerosis complex on the ketogenic diet. Brain Dev. 2010; 32(4):318-22. Epub 2009/05/16. doi: S0387-7604(09)00136-3 [pii] doi: 10.1016/j.braindev.2009.04.009 PMID: 19443154.
30. Schmidt M, Pfetzer N, Schwab M, Strauss I, Kammerer U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial. Nutrition & metabolism. 2011; 8(1):54. Epub 2011/07/29. doi: 10.1186/1743-7075-8-54 PMID: 21794124; PubMed Central PMCID: PMC3157418.
31. Mukherjee P, Abate LE, Seyfried TN. Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10(16):5622-9. Epub 2004/08/26. doi: 10.1158/1078-0432.CCR-04-0308 10/16/5622 [pii]. PMID: 15328205.
32. Mukherjee P, El-Abbadi MM, Kasperzyk JL, Ranes MK, Seyfried TN. Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model. British journal of cancer. 2002; 86 (10):1615-21. Epub 2002/06/27. doi: 10.1038/sj.bjc.6600298 PMID: 12085212; PubMed Central PMCID: PMC2746602.
33. Seyfried TN, Mukherjee P. Targeting energy metabolism in brain cancer: review and hypothesis. Nutrition & metabolism. 2005; 2:30. Epub 2005/10/26. doi: 1743-7075-2-30 [pii] doi: 10.1186/1743-7075-2-30 PMID: 16242042; PubMed Central PMCID: PMC1276814.
34. Freeman JM, Kossoff EH, Hartman AL. The ketogenic diet: one decade later. Pediatrics. 2007; 119 (3):535-43. doi: 10.1542/peds.2006-2447 PMID: 17332207.
35. Payne NE, Cross JH, Sander JW, Sisodiya SM. The ketogenic and related diets in adolescents and adults-a review. Epilepsia. 2011; 52(11):1941-8. doi: 10.1111/j.1528-1167.2011.03287.x PMID: 22004525.
36. Huffman J, Kossoff EH. State of the ketogenic diet(s) in epilepsy. Current neurology and neuroscience reports. 2006; 6(4):332-40. PMID: 16822355.
37. Hartman AL, Vining EP. Clinical aspects of the ketogenic diet. Epilepsia. 2007; 48(1):31-42. doi: 10.1111/j.1528-1167.2007.00914.x PMID: 17241206.
38. Paoli A, Rubini A, Volek JS, Grimaldi KA. Beyond weight loss: a review of the therapeutic uses of verylow-carbohydrate (ketogenic) diets. European journal of clinical nutrition. 2013; 67(8):789-96. doi: 10.1038/ejcn.2013.116 PMID: 23801097; PubMed Central PMCID: PMC3826507.
39. Bough KJ, Wetherington J, Hassel B, Pare JF, Gawryluk JW, Greene JG, et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Annals of neurology. 2006; 60(2):223-35. doi: 10.1002/ana.20899 PMID: 16807920.
40. Seyfried TN, Shelton LM, Mukherjee P. Does the existing standard of care increase glioblastoma energy metabolism? The lancet oncology. 2010; 11(9):811-3. Epub 2010/07/17. doi: S1470-2045(10)70166-2 [pii] doi: 10.1016/S1470-2045(10)70166-2 PMID: 20634134.
41. Seyfried TN, Kiebish MA, Marsh J, Shelton LM, Huysentruyt LC, Mukherjee P. Metabolic management of brain cancer. Biochimica et biophysica acta. 2011; 1807(6):577-94. Epub 2010/09/02. doi: S0005-2728(10)00685-7 [pii] doi: 10.1016/j.bbabio.2010.08.009 PMID: 20804725.
42. Maroon J, Bost J, Amos A, Zuccoli G. Restricted calorie ketogenic diet for the treatment of glioblastoma multiforme. Journal of child neurology. 2013; 28(8):1002-8. doi: 10.1177/0883073813488670 PMID: 23670248.
43. Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, Mukherjee P, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. Nutrition & metabolism. 2010; 7:33. Epub 2010/04/24. doi: 10.1186/1743-7075-7-33 PMID: 20412570; PubMed Central PMCID: PMC2874558.
44. Nebeling LC, Miraldi F, Shurin SB, Lerner E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr. 1995; 14(2):202-8. Epub 1995/04/01. PMID: 7790697.
45. Gunther Feichtinger R, Weis S, Adalbert Mayr J, Zimmermann F, Geilberger R, Sperl W, et al. Alterations of oxidative phosphorylation complexes in astrocytomas. Glia. 2014. Epub 2014/01/22. doi: 10.1002/glia.22621 PMID: 24446254.
46. Roeder LM, Poduslo SE, Tildon JT. Utilization of ketone bodies and glucose by established neural cell lines. J Neurosci Res. 1982; 8(4):671-82. doi: 10.1002/jnr.490080412 PMID: 7161845.
47. Skinner R, Trujillo A, Ma X, Beierle EA. Ketone bodies inhibit the viability of human neuroblastoma cells. Journal of pediatric surgery. 2009; 44(1):212-6; discussion 6. PMID: 19159745. doi: 10.1016/j.jpedsurg.2008.10.042
48. Li Z, Yan S, Attayan N, Ramalingam S, Thiele CJ. Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18(13):3603-15. Epub 2012/05/03. 1078-0432.CCR-11-3321 [pii] doi: 10.1158/1078-0432.CCR-11-3321 PMID: 22550167.
49. Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes/metabolism research and reviews. 1999; 15(6):412-26. Epub 2000/01/15. PMID: 10634967.
50. Kristensen GB, Christensen NG, Thue G, Sandberg S. Between-lot variation in external quality assessment of glucose: clinical importance and effect on participant performance evaluation. Clin Chem. 2005; 51(9):1632-6. Epub 2005/08/27. doi: 10.1373/clinchem.2005.049080 PMID: 16120948.
51. Kimberly MM, Vesper HW, Caudill SP, Ethridge SF, Archibold E, Porter KH, et al. Variability among five over-the-counter blood glucose monitors. Clinica chimica acta; international journal of clinical chemistry. 2006; 364(1-2):292-7. Epub 2005/09/07. doi: 10.1016/j.cca.2005.07.027 PMID: 16143321.
52. Mayr JA, Zimmermann FA, Fauth C, Bergheim C, Meierhofer D, Radmayr D, et al. Lipoic acid synthetase deficiency causes neonatal-onset epilepsy, defective mitochondrial energy metabolism, and glycine elevation. Am J Hum Genet. 2011; 89(6):792-7. Epub 2011/12/14. doi: S0002-9297(11)00489-7 [pii] doi: 10.1016/j.ajhg.2011.11.011 PMID: 22152680; PubMed Central PMCID: PMC3234378.
53. nd ed. Amsterdam; Boston: Academic Press; 2007. xxiv, 920 p. p.
54. Berger A, Mayr JA, Meierhofer D, Fotschl U, Bittner R, Budka H, et al. Severe depletion of mitochondrial DNA in spinal muscular atrophy. Acta Neuropathol. 2003; 105(3):245-51. PMID: 12557011.
55. Holloszy JO, Oscai LB, Don IJ, Mole PA. Mitochondrial citric acid cycle and related enzymes: adaptive response to exercise. Biochem Biophys Res Commun. 1970; 40(6):1368-73. Epub 1970/09/30. doi: 0006-291X(70)90017-3 [pii]. PMID: 4327015.
56. Srere PA. Citrate synthase. Methods in enzymology. 1969; 13:3-5. PMID: 4329195.
57. Rustin P, Chretien D, Bourgeron T, Gerard B, Rotig A, Saudubray JM, et al. Biochemical and molecular investigations in respiratory chain deficiencies. Clinica chimica acta; international journal of clinical chemistry. 1994; 228(1):35-51. PMID: 7955428.
58. Kollberg G, Darin N, Benan K, Moslemi AR, Lindal S, Tulinius M, et al. A novel homozygous RRM2B missense mutation in association with severe mtDNA depletion. Neuromuscul Disord. 2009; 19 (2):147-50. Epub 2009/01/14. doi: S0960-8966(08)00707-4 [pii] doi: 10.1016/j.nmd.2008.11.014 PMID: 19138848.
59. Acham-Roschitz B, Plecko B, Lindbichler F, Bittner R, Mache CJ, Sperl W, et al. A novel mutation of the RRM2B gene in an infant with early fatal encephalomyopathy, central hypomyelination, and tubulopathy. Mol Genet Metab. 2009; 98(3):300-4. PMID: 19616983. doi: 10.1016/j.ymgme.2009.06.012
60. Meidenbauer JJ, Mukherjee P, Seyfried TN. The glucose ketone index calculator: a simple tool to monitor therapeutic efficacy for metabolic management of brain cancer. Nutrition & metabolism. 2015; 12:12. doi: 10.1186/s12986-015-0009-2 PMID: 25798181; PubMed Central PMCID: PMC4367849.
61. Tisdale MJ, Brennan RA. Loss of acetoacetate coenzyme A transferase activity in tumours of peripheral tissues. British journal of cancer. 1983; 47(2):293-7. Epub 1983/02/01. PMID: 6130780; PubMed Central PMCID: PMC2011283.
62. Chang HT, Olson LK, Schwartz KA. Ketolytic and glycolytic enzymatic expression profiles in malignant gliomas: implication for ketogenic diet therapy. Nutrition & metabolism. 2013; 10(1):47. Epub 2013/07/09. doi: 1743-7075-10-47 [pii] doi: 10.1186/1743-7075-10-47 PMID: 23829383; PubMed Central PMCID: PMC3707813.
63. Qing G, Li B, Vu A, Skuli N, Walton ZE, Liu X, et al. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer cell. 2012; 22(5):631-44. doi: 10.1016/j.ccr.2012.09.021 PMID: 23153536; PubMed Central PMCID: PMC3510660.
64. Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R, et al. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst. 2007; 99(23):1793-800. doi: 10.1093/jnci/djm231 PMID: 18042933.
65. Otto C, Kaemmerer U, Illert B, Muehling B, Pfetzer N, Wittig R, et al. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC cancer. 2008; 8:122. doi: 10.1186/1471-2407-8-122 PMID: 18447912; PubMed Central PMCID: PMC2408928.
66. Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, et al. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. The Prostate. 2008; 68(1):11-9. doi: 10.1002/pros.20683 PMID: 17999389; PubMed Central PMCID: PMC3959866.
67. Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. British journal of cancer. 2003; 89 (7):1375-82. Epub 2003/10/02. doi: 10.1038/sj.bjc.6601269 PMID: 14520474; PubMed Central PMCID: PMCPMC2394295.
68. Shim H, Chun YS, Lewis BC, Dang CV. A unique glucose-dependent apoptotic pathway induced by c-Myc. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95 (4):1511-6. PMID: 9465046; PubMed Central PMCID: PMC19067.
69. Dang CV, Hamaker M, Sun P, Le A, Gao P. Therapeutic targeting of cancer cell metabolism. J Mol Med (Berl). 2011; 89(3):205-12. doi: 10.1007/s00109-011-0730-x PMID: 21301795; PubMed Central PMCID: PMC3345191.
70. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nature cell biology. 2007; 9(2):218-24. Epub 2007/01/24. doi: 10.1038/ncb1537 PMID: 17237771.
71. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes & development. 2011; 25(18):1895-908. Epub 2011/09/23. doi: 10.1101/gad.17420111 PMID: 21937710; PubMed Central PMCID: PMC3185962.
72. Barbet NC, Schneider U, Helliwell SB, Stansfield I, Tuite MF, Hall MN. TOR controls translation initiation and early G1 progression in yeast. Molecular biology of the cell. 1996; 7(1):25-42. Epub 1996/01/01. PMID: 8741837; PubMed Central PMCID: PMC278610.
73. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Molecular and cellular biology. 2004; 24(1):200-16. Epub 2003/12/16. PMID: 14673156; PubMed Central PMCID: PMC303352.
74. Aykin-Burns N, Ahmad IM, Zhu Y, Oberley LW, Spitz DR. Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. The Biochemical journal. 2009; 418(1):29-37. doi: 10.1042/BJ20081258 PMID: 18937644; PubMed Central PMCID: PMC2678564.
75. Ahmad IM, Aykin-Burns N, Sim JE, Walsh SA, Higashikubo R, Buettner GR, et al. Mitochondrial O2∗- and H2O2 mediate glucose deprivation-induced stress in human cancer cells. J Biol Chem. 2005; 280 (6):4254-63. doi: 10.1074/jbc.M411662200 PMID: 15561720.
76. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000; 287(5454):848-51. PMID: 10657297.
77. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005; 23(34):8812-8. Epub 2005/11/30. doi: 23/34/8812 [pii] doi: 10.1200/JCO.2005.03.1484 PMID: 16314641.
78. De Preter K, Vandesompele J, Hoebeeck J, Vandenbroecke C, Smet J, Nuyts A, et al. No evidence for involvement of SDHD in neuroblastoma pathogenesis. BMC cancer. 2004; 4:55. PMID: 15331017.
79. Astuti D, Morris M, Krona C, Abel F, Gentle D, Martinsson T, et al. Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma. British journal of cancer. 2004; 91 (10):1835-41. PMID: 15505628.
80. Dickinson A, Yeung KY, Donoghue J, Baker MJ, Kelly RD, McKenzie M, et al. The regulation of mitochondrial DNA copy number in glioblastoma cells. Cell Death Differ. 2013; 20(12):1644-53. Epub 2013/09/03. doi: cdd2013115 [pii] doi: 10.1038/cdd.2013.115 PMID: 23995230; PubMed Central PMCID: PMC3824586.
81. Facucho-Oliveira JM, John JC St. The relationship between pluripotency and mitochondrial DNA proliferation during early embryo development and embryonic stem cell differentiation. Stem Cell Rev. 2009; 5(2):140-58. Epub 2009/06/13. doi: 10.1007/s12015-009-9058-0 PMID: 19521804.
82. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002; 2(4):277-88. Epub 2002/05/11. doi: 10.1038/nrc776 PMID: 12001989.
83. Dey R, Moraes CT. Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-x(L) in osteosarcoma cells. J Biol Chem. 2000; 275(10):7087-94. Epub 2000/03/04. PMID: 10702275.
84. Shidara Y, Yamagata K, Kanamori T, Nakano K, Kwong JQ, Manfredi G, et al. Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer research. 2005; 65(5):1655-63. Epub 2005/03/09. doi: 10.1158/0008-5472.can-04-2012 PMID: 15753359.
85. Kwong JQ, Henning MS, Starkov AA, Manfredi G. The mitochondrial respiratory chain is a modulator of apoptosis. The Journal of cell biology. 2007; 179(6):1163-77. Epub 2007/12/19. doi: 10.1083/jcb.200704059 PMID: 18086914; PubMed Central PMCID: PMC2140029.
86. Kim JY, Kim YH, Chang I, Kim S, Pak YK, Oh BH, et al. Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis. Oncogene. 2002; 21(20):3139-48. Epub 2002/06/26. doi: 10.1038/sj.onc.1205406 PMID: 12082629.
87. King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene. 2006; 25(34):4675-82. Epub 2006/08/08. doi: 1209594 [pii] doi: 10.1038/sj.onc.1209594 PMID: 16892081.
88. Hughes SD, Kanabus M, Anderson G, Hargreaves IP, Rutherford T, Donnell MO, et al. The ketogenic diet component decanoic acid increases mitochondrial citrate synthase and complex I activity in neuronal cells. Journal of neurochemistry. 2014. Epub 2014/01/05. doi: 10.1111/jnc.12646 PMID: 24383952.